New hope for lung cancer patients with brain tumors: targeted drug T-DXd enters trial

NCT ID NCT06250777

ENROLLING_BY_INVITATION Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests the drug T-DXd (Enhertu) in 27 adults with advanced HER2-mutant lung cancer that has spread to the brain but is not causing symptoms. The main goal is to see how long the drug can keep brain tumors from growing. T-DXd is already approved for certain lung cancers, and this study focuses on patients with brain metastases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trastuzumab deruxtecan (T-DXd, Enhertu)
What this could lead to: If successful, this could provide a treatment option that controls both lung tumors and brain metastases in patients with HER2-mutant lung cancer.
What could go wrong: This is a small, early-phase trial with only 27 participants, so results may not apply to all patients. There is a risk of side effects like interstitial lung disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Yonsei University Health system, Severance Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.